Company / SG&A Expense
ARS Pharmaceuticals, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$230.1M
FY2025
5-year range
$4.7M / $230.1M
FY2021-FY2025
Trend
+221.1%
vs FY2024
Sector context
#65 of 213
Health Care
What the data says
SG&A Expense changed +221% YoY in FY2025, a notable deviation from the 5-year average annual change of +228%.
Based on SEC 10-K filings.
$230M in FY2025 with a 5-year CAGR of +94.2%.
Increased from $47M to $230M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +266.2%
- 5-Year CAGR
- +94.2%
- 10-Year CAGR
- -
Sector benchmark
#149 of 213 in Health CareTop 69% of 213This company $230.1M Sector average $722.3M
▼
-68.1% below sector average
Key checks
Key Insights
- ARS Pharmaceuticals, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +94.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 221.1% year-over-year.
- Ranks #65 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $230.1M | +221.1% |
| FY2024 | $71.7M | +51.6% |
| FY2023 | $47.3M | +908.8% |
| FY2022 | $4.7M | +0.0% |
| FY2021 | $4.7M | -43.8% |
| FY2020 | $8.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026